AI Article Synopsis
- The study highlights the growing issue of infections from drug-resistant ESBL-producing Enterobacteriaceae (ESBL-ENT) and investigates treatment outcomes in patients from two clinical trials using ceftolozane/tazobactam.
- The research shows that a significant percentage of ESBL-ENT strains were susceptible to ceftolozane/tazobactam compared to other antibiotics like levofloxacin, with high clinical cure rates reported for patients treated with this drug.
- The findings indicate that ceftolozane/tazobactam is an effective treatment option for complicated urinary tract and intra-abdominal infections caused by ESBL-ENT.
Article Abstract
Objectives: The increase in infections caused by drug-resistant ESBL-producing Enterobacteriaceae (ESBL-ENT) is a global concern. The characteristics and outcomes of patients infected with ESBL-ENT were examined in a pooled analysis of Phase 3 clinical trials of ceftolozane/tazobactam in patients with complicated urinary tract infections (ASPECT-cUTI) and complicated intra-abdominal infections (ASPECT-cIAI).
Methods: Trials were randomized and double blind. The ASPECT-cUTI regimen was 7 days of either intravenous ceftolozane/tazobactam (1.5 g) every 8 h or levofloxacin (750 mg) once daily. The ASPECT-cIAI regimen was 4-14 days of either intravenous ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) or meropenem (1 g) every 8 h. Baseline cultures were obtained in both indications. Enterobacteriaceae were selected for ESBL characterization based on predefined criteria and were verified genotypically. Outcomes were assessed at the test-of-cure visit 5-9 days post-therapy in ASPECT-cUTI and 24-32 days post-randomization in ASPECT-cIAI among microbiologically evaluable (ME) patients.
Results: Of 2076 patients randomized, 1346 were included in the pooled ME population and 150 of 1346 (11.1%) had ESBL-ENT at baseline. At US FDA/EUCAST breakpoints of ≤2/≤1 mg/L, 81.8%/72.3% of ESBL-ENT (ESBL-Escherichia coli, 95%/88.1%; ESBL-Klebsiella pneumoniae, 56.7%/36.7%) were susceptible to ceftolozane/tazobactam versus 25.3%/24.1% susceptible to levofloxacin and 98.3%/98.3% susceptible to meropenem at CLSI/EUCAST breakpoints. Clinical cure rates for ME patients with ESBL-ENT were 97.4% (76/78) for ceftolozane/tazobactam [ESBL-E. coli, 98.0% (49 of 50); ESBL-K. pneumoniae, 94.4% (17 of 18)], 82.6% (38 of 46) for levofloxacin and 88.5% (23 of 26) for meropenem.
Conclusions: Randomized trial data demonstrated high clinical cure rates with ceftolozane/tazobactam treatment of cIAI and cUTI caused by ESBL-ENT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jac/dkw374 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Occupational Factors Influencing Turnover Intention in Working Women with Lower Urinary Tract Symptoms.
J Occup Environ Med
November 2024
Department of Occupational and Enviornmental Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Objective: To identify the occupational factors that influence turnover intention among working women with lower urinary tract symptoms (LUTS).
Methods: This cross-sectional study targeted 410 working women with LUTS from a 2022 survey. Occupational characteristics, including working hours, shift work, bathroom accessibility, sitting time, musculoskeletal strain, job stress, and emotional labor, were assessed through a structured self-reported questionnaire using validated tools.
Water vapor thermal therapy for treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia (≥ 80 g).
World J Urol
January 2025
Department of Urology, AP-HM, North Hospital, Marseille, France.
Introduction: Water vapor thermal therapy (WVTT; REZUM™; Boston, USA) offers symptom relief with reduced risks of complications in patients with lower urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO). WVTT therapy has been validated in the pivotal study in men with smaller prostates (< 80 cc). Yet, its feasibility for larger prostates (≥ 80 cc) remains underexplored.
View Article and Find Full Text PDFTurkish Validation and Reliability Analysis of the International Female Coital Incontinence Questionnaire.
Int Urogynecol J
January 2025
Department of Obstetrics and Gynecology, Ankara University School of Medicine, Mamak, Ankara, Turkey.
Introduction And Hypothesis: Coital incontinence (CI) is an important problem that negatively affects women's quality of life and is often underreported owing to embarrassment, indicating the importance of its assessment with validated questionnaires. The aim of this study was to validate the Turkish-translated version of the International Female Coital Incontinence Questionnaire (IFCI-Q) for the objective evaluation of women with CI in Turkish-speaking populations.
Methods: Ninety women with CI filled out the Turkish-translated version of IFCI-Q.
Pediatric Urinary Stone Disease: A 10-Year Single-Center Experience from Türkiye.
Turk Arch Pediatr
January 2025
Department of Pediatric Nephrology, Başkent University Faculty of Medicine, Ankara, Türkiye.
Objective: Urinary stone disease (USD) is characterized by stone formation in the urinary system with an approximate prevalence of 5%-10% in children. In thisr study, the authors investigated the metabolic abnormalities that play a role in stone formation in pediatric patients with USD admitted to the authors' pediatric nephrology clinic during the last 10 years, the demographic characteristics of the patients, and the presenting symptoms. Materials and Methods: A total of 325 pediatric patients, 166 boys (51.
View Article and Find Full Text PDFDeep Learning and Numerical Analysis for Bladder Outflow Obstruction and Detrusor Underactivity Diagnosis in Men: A Novel Urodynamic Evaluation Scheme.
Neurourol Urodyn
January 2025
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China.
Objectives: To automatically identify and diagnose bladder outflow obstruction (BOO) and detrusor underactivity (DUA) in male patients with lower urinary tract symptoms through urodynamics exam.
Patients And Methods: We performed a retrospective review of 1949 male patients who underwent a urodynamic study at two institutions. Deep Convolutional Neural Networks scheme combined with a short-time Fourier transform algorithm was trained to perform an accurate diagnosis of BOO and DUA, utilizing five-channel urodynamic data (consisting of uroflowmetry, urine volume, intravesical pressure, abdominal pressure, and detrusor pressure).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!